Caenorhabditis Intervention Testing Program - Buck Institute Compound Testing

项目概要 与人类衰老相关的健康挑战给我们的社会带来了巨大的损失。身体和认知能力下降 限制了老年人及其护理人员的生活质量。衰老是主要风险因素，也是可能的原因 癌症、糖尿病和神经退行性疾病，因此与衰弱性疾病作斗争是一种常见的情况 人口老龄化带来的健康负担。毫无疑问，随着时间的推移，促进健康老龄化 抵抗衰退应该是当前医学研究的一个主要目标。 为了研究健康衰老，人们对线虫等简单动物模型进行了研究。 提供对基因和化学化合物干预的分子见解，这些干预措施可以调节保守的 衰老过程可能在人类身上也有类似的表现。拟议工作的目标是继续并扩大， 一个合作科学小组的努力，包括三个密切互动的实验室，他们协调测试 药物干预能够延长线虫的健康衰老和延长寿命。一个 这个综合超级小组的具体重点是在一系列自然变体上测试有前途的药物 秀丽隐杆线虫属，它们共同代表了人类广泛的遗传异质性 人口。这个想法是，在不同人群中带来积极结果的治疗将具有 增加在高等生物体中有效的机会，并将被建议作为优先干预措施 在临床前小鼠研究和可能的未来人体试验中进行测试。 CITP Buck 提案的重点是报告测试化合物的进展以及我们提出的建议 我们向一般生物医学界开放 CITP 时的工作流程。 总的来说，我们将参与一个独特的团队项目，该项目有能力定义药理学干预措施 有力地促进不同人群的健康寿命，对发展产生影响 促进人类健康衰老的疗法。

Project Summary Health challenges linked to human aging take a tremendous toll on our society. Physical and cognitive decline limit the quality of life for the elderly and their caregivers. Aging is the major risk factor for, and possible cause of cancer, diabetes, and neurodegenerative disease, and thus struggle with debilitating disease is a common health burden for the aging population. Without question, the promotion of healthy aging with extended resistance to decline should be a major objective of current medical research. To investigate healthy aging, simple animals models such as the nematode C. elegans have been studied, providing molecular insights into the genes and chemical compound interventions that can modulate conserved aging processes likely to act similarly in humans. The goal of the proposed work is to continue, and expand, efforts of a co-operative scientific group involving three closely interacting laboratories who coordinately test pharmacological interventions for the ability to extend healthy aging and promote longevity in nematodes. A specific emphasis of this integrated super-group is to test promising drugs on a collection of natural variants of the Caenorhabditis genus, which together represent the extensive genetic heterogeneity in the human population. The idea is that treatments that confer positive outcomes across a diverse population will have an increased chance of being efficacious in higher organisms and will be suggested as priority interventions for testing in pre-clinical mouse studies and possibly future human trials. The emphasis of this CITP Buck proposal is to report on progress in testing compounds and our proposed workflow as we open the CITP to the general biomedical community. Overall, we will participate in a unique team project that has the power to define pharmacological interventions that robustly promote strong healthspan across a varied population, with implications for development of therapies that promote healthy human aging.